🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 02/04/2013 | 54,52 | 55,48 | 53,73 | 53,93 | -0,13% | 3,21% | 1.542.100 |
| 01/04/2013 | 55,00 | 55,55 | 53,72 | 54,00 | -1,76% | 3,33% | 1.628.500 |
| 28/03/2013 | 54,56 | 55,93 | 54,55 | 54,97 | +0,26% | 2,53% | 2.357.500 |
| 27/03/2013 | 53,95 | 54,89 | 53,51 | 54,83 | +0,90% | 2,56% | 1.165.000 |
| 26/03/2013 | 54,36 | 54,75 | 53,36 | 54,34 | +0,15% | 2,56% | 1.234.200 |
| 25/03/2013 | 53,94 | 54,98 | 53,35 | 54,26 | +0,97% | 3,02% | 1.980.900 |
| 22/03/2013 | 52,55 | 54,15 | 52,55 | 53,74 | +2,87% | 3,04% | 1.424.300 |
| 21/03/2013 | 52,04 | 52,95 | 51,85 | 52,24 | -0,46% | 2,11% | 1.226.100 |
| 20/03/2013 | 52,33 | 52,66 | 51,93 | 52,48 | +1,12% | 1,39% | 1.280.700 |
| 19/03/2013 | 51,67 | 52,45 | 51,39 | 51,90 | +1,03% | 2,05% | 1.973.200 |
| 18/03/2013 | 51,82 | 51,98 | 51,14 | 51,37 | -1,80% | 1,62% | 1.650.300 |
| 15/03/2013 | 52,59 | 52,94 | 51,87 | 52,31 | -0,91% | 2,03% | 2.098.700 |
| 14/03/2013 | 52,98 | 52,98 | 52,05 | 52,79 | +0,04% | 1,76% | 1.139.400 |
| 13/03/2013 | 52,47 | 53,02 | 52,23 | 52,77 | +0,69% | 1,51% | 1.279.100 |
| 12/03/2013 | 52,48 | 52,96 | 51,90 | 52,41 | -0,27% | 2,02% | 1.484.900 |
| 11/03/2013 | 52,45 | 53,03 | 52,15 | 52,55 | -0,49% | 1,68% | 1.747.100 |
| 08/03/2013 | 50,28 | 52,92 | 50,09 | 52,81 | +5,26% | 5,63% | 3.535.300 |
| 07/03/2013 | 49,51 | 50,36 | 49,22 | 50,17 | +1,33% | 2,30% | 1.583.600 |
| 06/03/2013 | 48,41 | 49,83 | 48,10 | 49,51 | +2,44% | 3,57% | 2.085.500 |
| 05/03/2013 | 46,63 | 48,34 | 46,20 | 48,33 | +4,36% | 4,59% | 1.694.700 |
| 04/03/2013 | 46,02 | 46,54 | 45,59 | 46,31 | +0,30% | 2,06% | 1.682.100 |
| 01/03/2013 | 46,55 | 46,58 | 45,52 | 46,17 | -1,39% | 2,28% | 2.050.400 |
| 28/02/2013 | 46,89 | 48,15 | 46,59 | 46,82 | -0,32% | 3,33% | 1.900.700 |
| 27/02/2013 | 44,44 | 47,23 | 44,20 | 46,97 | +6,32% | 6,82% | 2.742.200 |
| 26/02/2013 | 44,98 | 45,11 | 43,69 | 44,18 | -1,52% | 3,16% | 1.160.600 |
| 25/02/2013 | 46,14 | 46,30 | 44,84 | 44,86 | -2,29% | 3,16% | 1.364.900 |
| 22/02/2013 | 45,08 | 45,92 | 44,82 | 45,91 | +2,43% | 2,44% | 1.472.100 |
| 21/02/2013 | 45,21 | 45,67 | 44,77 | 44,82 | -1,36% | 1,99% | 1.693.500 |
| 20/02/2013 | 46,48 | 47,08 | 45,41 | 45,44 | -2,32% | 3,59% | 1.731.400 |
| 19/02/2013 | 45,60 | 46,55 | 45,50 | 46,52 | +2,00% | 2,30% | 1.340.400 |